Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Daiichi Sankyo
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06172478CT.gov A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cervical Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| her3-dxd (this asset) | Daiichi Sankyo | P2 | CCC · 48 |
| Vinorelbine Ditartrate | UNICANCER | P2 | BBB |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Uganda Cancer Institute | P3 | B |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | B |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | B |
| Carboplatin | Merck Sharp & Dohme LLC | P3 | B |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P3 | B |
| Indocyanine Green | Istanbul University | P4 | B |
+42 more in the Cervical Cancer cohort
Other indications for her3-dxd
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | B · 59 |
| Ovarian Carcinoma | — | P2 | CCC · 53 |
| Exocrine Pancreatic Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. her3-dxd in Cervical Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/her3-dxd-cervical-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →